Author’s response to reviews

Title: NR2F1 contributes to cancer cell dormancy, invasion and metastasis of salivary adenoid cystic carcinoma by activating CXCL12/CXCR4 pathway

Authors:

xiaolei Gao (gxlztl2009@163.com)
Min Zheng (drzhengmin123@sina.com)
Haofan Wang (wanghf9610@163.com)
Luling Dai (dailuling1992@163.com)
Xianghua Yu (18328578574@163.com)
Xiao Yang (dryangxiao2017@sina.com)
Xin Pang (pangxin112233@163.com)
Li Li (Kiyall001@126.com)
Mei Zhang (doctorzhangmei16@sina.com)
Shasha Wang (drwangshasha2010@163.com)
Jingbiao Wu (drwujingbiao@sina.com)
Yajie Tang (drtangyajie2010@163.com)
Xinhua Liang (lxh88866@scu.edu.cn)
Yaling Tang (tangyaling@scu.edu.cn)

Version: 3 Date: 09 Jul 2019

Author’s response to reviews:

Dear Dr. William Spenceley Jones,
Thank you for your suggestions to revise our article entitled "NR2F1 Contributes to Cancer Cell Dormancy, Invasion and Metastasis of Salivary Adenoid Cystic Carcinoma by Activating CXCL12/CXCR4 Pathway" (Manuscript ID: BCAN-D-19-00373R2). We have highly regarded the editor’s suggestions, carefully responded to these suggestions point-by-point in this response letter (see following “responses” part), and revised the manuscript accordingly.

Please contact me with any questions. We look forward to hearing from you.

Thank you for your time and best wishes to you!

Yours sincerely,

Ya-ling Tang

Full postal address: State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatolgy, Sichuan University, No.14, Sec. 3, Renminnan Road, Chengdu Sichuan 610041, China

E-mail address: tangyaling@scu.edu.cn

Editor Comments:

Comment 1: In the "Availability of Data and Materials" section, please detail where the raw data supporting your findings can be found (including information found in any supplementary files). If the raw data is publicly available or can be requested, please state that this is the case, and where the data can be found/requested from. Alternatively, if you do not wish to/cannot share your data, please state (in the ‘Availability of data and Materials’ section) that data will not be shared, and state the reason.

Please note that participant or patient data should be de-identified.
Please see our submission guidelines for the statements we can accept in this section.

https://www.biomedcentral.com/getpublished/editorial-policies#availability+of+data+and+materials

[Author Response] We have further detail about the raw data in this article in the “Availability of Data and Materials” section as following, “This is the case and the raw data can be requested from Dr. Tang Yaling and Miss Gao Xiaolei “(Please See Page 20, “Availability of data and material” section)

Comment 2: In the section 'Funding', please also describe the role of the funding body/bodies in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

[Author Response] Thank you! All the funds in this article were used for the design of the study and for the collection, analysis and interpretation of the data and writing of the manuscript, as we added this statement into the Funding section. (Please see page 20, “Funding” section.)

Comment 3: We note that two authors have the same initials (MZ). To distinguish between them in the Authors’ Contributions section please designate them as MZ1 and MZ2, with MZ1 corresponding to Min Zheng, chosen because this name is furthest up the author list.

[Author Response] Thanks for your suggestion! We have revised the initials of these two authors. (Please see page 21, paragraph 1,line 2 and line 3.)